Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Quote. Delayed Australian Stock Exchange - 01/18 09:29:27 pm
0.395 AUD   +1.94%
01/03Hexima Appoints Commercial Chief
MT
01/03Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
CI
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima : CEO's Presentation

12/01/2021 | 05:51pm EST

For personal use only

HEXIMA LIMITED

ASX ANNOUNCEMENT

02 November 2021

2021 ANNUAL GENERAL MEETING - CEO'S PRESENTATION

MELBOURNE, AUSTRALIA (2 December 2021): Hexima Limited (ASX:HXL) provides the attached CEO Presentation to be delivered at today's Annual General Meeting commencing at 11.00am AEDT.

The AGM can be joined at https://meetings.linkgroup.com/HXL21

This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO.

Enquiries:

Dr Nicole van der Weerden Chief Operating Officer n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please click here

ABOUT HEXIMA

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on Twitterand LinkedInor email us at info@hexima.com.au.

LEVEL 4 LIMS 2, KINGSBURY DRIVE, LA TROBE UNIVERSITY VIC 3086

1

ersonal use only

MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER PRESENTATION

MR MICHAEL ALDRIDGE

MAJOR ACHIEVEMENTS FY2021

onlyMilestones & Achievements

Public Offering and listing on ASX

use

o $3 million offering at A$0.20 per share

Phase IIb clinical trial

ersonal

o Initiation and completion of enrolment

Intellectual property protection

Scientific Advisory Board

o Australian, US and Japan KOLs

CompliancePak

AGM 2021

S L I D E 3

12 WEEK DAILY DOSING FOLLOWED
BY ONCE WEEKLY DOSING
ONCE-WEEKLYDOSING
WEEK
13

A U S T R A L I A N P H A S E I I B C L I N I C A L T R I A L

HXP124-ONY-002

Enrolment completed

only 12 WEEK

DAILY DOSING use

31 WEEK

DAILY DOSING

ersonalDAILY DOSING NOTE: DAILY DOSING PERIODS INCLUDE 1-WEEKWASHOUTS EVERY 6 WEEKS

HXP124-ONY-002 ANZCTR registration number: ACTRN12620000697987

WEEK

WEEK

WEEK

24

36

40

NO DOSING

FOLLOW-UP VISITS

WASHOUT PERIOD

AGM 2021

July 2021

  • Multi-center,randomised, double blind, vehicle-controlled study
  • Primary endpoint safety and tolerability, secondary endpoints Mycological Cure and Clinical Efficacy
  • Three active (2% pezadeftide) versus vehicle arms to test optimal dosing strategy
  • Safety & efficacy assessed at 13, 24, 36 and 40 weeks, data expected Q2 2022

SLID 4

E

S t r o n g p a t e n t p o s i t i o n

ADDITIONAL PROTECTION VIA FORMULATION PATENTS AND MARKET

only

EXCLUSIVITY FOR BIOLOGICS

Clearly defined

use

growth strategy

Develop independently in

US and EU (ICH) markets

License and collaborative

ersonal

development in Japan and potentially China - presently in preliminary discussions with multiple parties

Granted patents

Granted and

12-year US market

(exp 2035) in major

pending patents

exclusivity on FDA

markets covering the

covering stabilising

approval likely available

use of pezadeftide in

formulation for

as a biologic drug

the treatment of

pezadeftide

onychomycosis

AGM 2021

SLIDE 5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Hexima Limited published this content on 01 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2021 22:50:05 UTC.


ę Publicnow 2021
All news about HEXIMA LIMITED
01/03Hexima Appoints Commercial Chief
MT
01/03Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
CI
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
2021Hexima Names New Chief Development Officer
MT
2021HEXIMA : CEO's Presentation
PU
2021Hexima Limited Announces Cessation of Marilyn Anderson as Executive Director
CI
2021Hexima Limited Announces Appointment of Shari Lipner as Member of its Scientific Adviso..
CI
2021Hexima Limited Announces Appointment of Nancy Sacco as Chief Development Officer
CI
2021Hexima Completes Oversubscribed Share Purchase Plan
MT
More news
Financials
Sales 2022 - - -
Net income 2022 -9,30 M -6,74 M -6,74 M
Net cash 2022 41,5 M 30,1 M 30,1 M
P/E ratio 2022 -6,77x
Yield 2022 -
Capitalization 65,3 M 47,1 M 47,3 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees -
Free-Float 69,6%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,40 AUD
Average target price 0,75 AUD
Spread / Average Target 89,9%
EPS Revisions
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED-4.82%47
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
ICON PUBLIC LIMITED COMPANY-17.00%20 923